FDA approves once-daily Azstarys (serdexmethylphenidate [SDX] and dexmethylphenidate [d-MPH]) capsules for treatment of ADHD symptoms in patients aged 6 years and older

Azstarys contains 30% immediate-release d-MPH and 70% extended-release SDX, a prodrug of d-MPH. After absorption, SDX is converted to d-MPH with a design to gradually release d-MPH throughout day, providing symptom control rapidly with d-MPH and for extended duration with SDX.

Biospace Inc.